Bronchiolitis is a respiratory an infection of the small bronchi on account of respiratory syncytial virus (VRS). Every year in France, bronchiolitis impacts 30% of youngsters underneath 2 years outdated, that’s to say about 500,000 infants. Worldwide, bronchiolitis is accountable for 60,000 toddler deaths per 12 months. If there’s already a preventive vaccine marketed by AstraZeneca underneath the title of Synagis, it was solely reserved for infants born prematurely and youngsters at excessive danger. Sanofi and AstraZeneca have subsequently collaborated to develop a vaccine that every one infants will profit from.

Bronchiolitis vaccine: roughly 75% efficient

The vaccine developed by Sanofi and AstraZeneca is totally different from different vaccines. In impact, it’s the first passive immunizing agent injected earlier than the age of 1 12 months in infants. In observe, this preventive therapy works due to the introduction into the physique of a monoclonal antibody developed within the laboratory, right here the virus accountable for bronchiolitis. Infants haven’t but developed an immunity able to defending themselves, this preventive therapy will permit them to guard themselves by giving them antibodies in a single dose. In its press launch, Sanofi states that: “Carried out on 1,490 infants between July 2019 and February 2021, the part 3 scientific trial of the vaccine demonstrated 74.5% efficacy in opposition to infections (pneumonia, bronchiolitis) brought on by RSV requiring help.” As for Jean-Francois Toussaint
International Head, Vaccine Analysis and Growth, Sanofi, he stated “the favorable opinion that the CHMP issued as we speak constitutes one of the vital advances by way of public well being and struggle in opposition to RSV for a number of many years and has the potential to significantly alleviate the heavy bodily and psychological burden that this virus locations on households and well being programs. With this advisory, we’re effectively on our strategy to attaining our aim of defending all infants in opposition to RSV infections, with only one dose.”

Bronchiolitis: an an infection that additionally impacts the aged

Once we discuss bronchiolitis, we instantly consider younger youngsters. And but, the bronchiolitis epidemic additionally impacts the aged. Sadly, this preventive vaccine/therapy won’t be meant for this fragile public. Many laboratories are at present engaged on the event of a selected vaccine for the aged. On the official web site of the Ministry of Well being and Prevention, suggestions are printed in an effort to restrict the transmission of the RSV virus:

  • Wash your palms frequently ;
  • Use a hydro-alcoholic resolution if you happen to can not wash your palms;
  • Ventilate your own home no less than 10 minutes a day;
  • Keep away from confined locations ;
  • Don’t share dishes;
  • Usually clear youngsters’s toys and comforters;
  • Don’t smoke close to younger youngsters ;
  • Cowl your mouth when you might have a chilly or cough;
  • Put on a masks if you’re sick within the presence of fragile folks;
  • Keep away from hugs with fragile folks.

Sources

https://www.sanofi.com/fr/media-room/press-releases/2022/2022-09-16-06-00-00-2517378

https://solidarites-sante.gouv.fr/soins-et- Maladies/ Maladies/ Maladies-infectieuses/les- Maladies-de-l-hiver/article/la-bronchiolite

The editor recommends: